JP2024105296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105296A5 JP2024105296A5 JP2024066707A JP2024066707A JP2024105296A5 JP 2024105296 A5 JP2024105296 A5 JP 2024105296A5 JP 2024066707 A JP2024066707 A JP 2024066707A JP 2024066707 A JP2024066707 A JP 2024066707A JP 2024105296 A5 JP2024105296 A5 JP 2024105296A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- cancer
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 54
- 102000025171 antigen binding proteins Human genes 0.000 claims 27
- 108091000831 antigen binding proteins Proteins 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 16
- 238000006467 substitution reaction Methods 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 108091008874 T cell receptors Proteins 0.000 claims 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 230000002068 genetic effect Effects 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 102220516971 Core-binding factor subunit beta_I54F_mutation Human genes 0.000 claims 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims 2
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 claims 2
- 101001005723 Homo sapiens Melanoma-associated antigen 8 Proteins 0.000 claims 2
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 claims 2
- 102100025076 Melanoma-associated antigen 8 Human genes 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003236 esophagogastric junction Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 102200095678 rs11004439 Human genes 0.000 claims 1
- 102200078978 rs121907888 Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882131P | 2019-08-02 | 2019-08-02 | |
| US62/882,131 | 2019-08-02 | ||
| DE102019121007.0A DE102019121007A1 (de) | 2019-08-02 | 2019-08-02 | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| DE102019121007.0 | 2019-08-02 | ||
| US201962905782P | 2019-09-25 | 2019-09-25 | |
| US62/905,782 | 2019-09-25 | ||
| JP2022506617A JP7476298B2 (ja) | 2019-08-02 | 2020-07-31 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
| PCT/EP2020/071660 WO2021023658A1 (en) | 2019-08-02 | 2020-07-31 | Antigen binding proteins specifically binding mage-a |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506617A Division JP7476298B2 (ja) | 2019-08-02 | 2020-07-31 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105296A JP2024105296A (ja) | 2024-08-06 |
| JP2024105296A5 true JP2024105296A5 (enExample) | 2025-03-04 |
Family
ID=74165587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506617A Active JP7476298B2 (ja) | 2019-08-02 | 2020-07-31 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
| JP2024066707A Pending JP2024105296A (ja) | 2019-08-02 | 2024-04-17 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506617A Active JP7476298B2 (ja) | 2019-08-02 | 2020-07-31 | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US11840577B2 (enExample) |
| EP (1) | EP4007776A1 (enExample) |
| JP (2) | JP7476298B2 (enExample) |
| KR (1) | KR20220041161A (enExample) |
| CN (2) | CN114616244A (enExample) |
| AR (1) | AR120585A1 (enExample) |
| AU (1) | AU2020324515A1 (enExample) |
| BR (1) | BR112022001923A2 (enExample) |
| CA (1) | CA3148937A1 (enExample) |
| CL (2) | CL2022000252A1 (enExample) |
| CO (1) | CO2022002044A2 (enExample) |
| CR (1) | CR20220086A (enExample) |
| DE (1) | DE102019121007A1 (enExample) |
| IL (1) | IL290268A (enExample) |
| MX (3) | MX2022001422A (enExample) |
| PE (1) | PE20221021A1 (enExample) |
| PH (1) | PH12022550230A1 (enExample) |
| TW (1) | TWI878330B (enExample) |
| WO (1) | WO2021023658A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| JP2024509910A (ja) | 2021-03-09 | 2024-03-05 | シーディアール－ライフ・アクチェンゲゼルシャフト | Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質 |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| WO2023099606A1 (en) | 2021-12-01 | 2023-06-08 | Immunocore Limited | Treatment of mage-a4 positive cancer |
| WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| CN114457002B (zh) * | 2022-02-23 | 2023-08-22 | 中山大学 | 一种分离细胞外囊泡亚群的方法及其应用 |
| TW202406569A (zh) * | 2022-05-02 | 2024-02-16 | 美商帝斯肯醫療公司 | 多重ｔ細胞受體組合物、組合療法及其用途 |
| JP2025518203A (ja) * | 2022-06-01 | 2025-06-12 | コレジェネ バイオテクノロジー カンパニー リミテッド | Ｍａｇｅ－ａ１特異的ｔｃｒ及びその用途 |
| AU2023289164A1 (en) * | 2022-06-24 | 2025-01-09 | Amgen Inc. | Magea4 specific t cell receptors |
| US20240114883A1 (en) * | 2022-08-12 | 2024-04-11 | Ingenious Targeting Laboratories | Genetically modified non-human having humanized gamma and delta TCR variable genes |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| AU2024214482A1 (en) | 2023-02-03 | 2025-08-07 | Zelluna Immunotherapy As | Anti-mage-a4 t cell receptors |
| CN116519936B (zh) * | 2023-02-28 | 2025-11-07 | 杭州凯保罗生物科技有限公司 | 用于前列腺癌早期检测的肿瘤自身抗原/抗体组合及应用 |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025233420A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use of anti-cancer molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4179338A (en) | 1977-09-19 | 1979-12-18 | Gordon Maurice R | Microbiological medium suitable for sterilization by ionizing radiation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| AU6248994A (en) | 1993-02-22 | 1994-09-14 | Rockefeller University, The | Production of high titer helper-free retroviruses by transient transfection |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6018032A (en) | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP4972264B2 (ja) | 1999-12-06 | 2012-07-11 | ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 高親和性ｔｃｒタンパク質および方法 |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| PT1558643E (pt) | 2002-11-09 | 2009-08-24 | Immunocore Ltd | Apresentação de um receptor das células t |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US7811828B2 (en) | 2004-01-28 | 2010-10-12 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumuor-associated |
| US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| SI2195023T1 (en) | 2007-08-29 | 2018-07-31 | Sanofi | Humanized anti-CXCR5 antibodies, their derivatives and their uses |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2618835B1 (en) | 2010-09-20 | 2017-07-05 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| WO2013031882A1 (ja) | 2011-08-31 | 2013-03-07 | 国立大学法人三重大学 | がん治療用ワクチン製剤 |
| WO2013057596A1 (en) | 2011-10-21 | 2013-04-25 | Atena Srl | Anatomic cushion accumulator for thermal treatment with heat or cold |
| EP2660250B1 (en) | 2012-05-02 | 2018-11-14 | Deutsches Rheuma-Forschungszentrum Berlin | Tcr transgenic mouse model for immune disease |
| WO2014018863A1 (en) | 2012-07-27 | 2014-01-30 | The Board Of Trustees Of The University Of Illinois | Engineering t-cell receptors |
| US9879065B2 (en) | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| ES2882183T3 (es) | 2013-03-14 | 2021-12-01 | Univ Duke | Moléculas biespecíficas que son inmunorreactivas con células efectoras inmunitarias que expresan un receptor activador |
| AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
| RU2645256C2 (ru) | 2013-06-26 | 2018-02-19 | Гуандун Сянсюэ Лайф Сайенсис, Лтд. | Высокостабильный т-клеточный рецептор и способ его получения и применения |
| CN106103711A (zh) | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
| KR102357961B1 (ko) | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| US10202640B2 (en) | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| EP3247725B1 (en) | 2015-01-23 | 2020-07-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| EP3095792A1 (en) | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| FI3430030T3 (fi) | 2016-03-16 | 2024-01-16 | Immatics Biotechnologies Gmbh | Transfektoituja t-soluja ja t-solureseptoreita käytettäviksi syöpien immunoterapiassa |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3494984A4 (en) | 2016-08-05 | 2020-07-22 | Tohoku University | TREATMENT AND DIAGNOSIS OF CANCER OR INFECTIOUS DISEASES USING THE T-CELL RECEPTOR RECOGNITION MECHANISM |
| GB201617716D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | Cell |
| GB201617714D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| DE102016121899A1 (de) | 2016-11-15 | 2018-05-17 | Immatics Biotechnologies Gmbh | Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
| US20210041435A1 (en) | 2018-01-31 | 2021-02-11 | Tohoku University | Method for regulating antigen-specific mhc expression |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| BR112020023195A2 (pt) | 2018-05-14 | 2021-09-28 | Immunocore Limited | Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune |
| JP2021528382A (ja) | 2018-06-04 | 2021-10-21 | エーピーオー‐ティー ビー．ヴイ． | 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段 |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| AU2020209991B2 (en) | 2019-01-17 | 2024-11-14 | Immunocore Limited | Formulations |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| CA3140142A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Trispecific binding molecules against bcma and uses thereof |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| GB201911286D0 (en) | 2019-08-07 | 2019-09-18 | Ucl Business Plc | Method |
| WO2021073624A1 (zh) | 2019-10-17 | 2021-04-22 | 北京门罗生物科技有限公司 | 用于免疫治疗的嵌合抗原受体、制备方法及其应用 |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
-
2019
- 2019-08-02 DE DE102019121007.0A patent/DE102019121007A1/de active Pending
-
2020
- 2020-07-30 US US16/943,779 patent/US11840577B2/en active Active
- 2020-07-31 JP JP2022506617A patent/JP7476298B2/ja active Active
- 2020-07-31 MX MX2022001422A patent/MX2022001422A/es unknown
- 2020-07-31 CN CN202080055666.0A patent/CN114616244A/zh active Pending
- 2020-07-31 PH PH1/2022/550230A patent/PH12022550230A1/en unknown
- 2020-07-31 CN CN202210924728.8A patent/CN115925958A/zh active Pending
- 2020-07-31 CR CR20220086A patent/CR20220086A/es unknown
- 2020-07-31 BR BR112022001923A patent/BR112022001923A2/pt unknown
- 2020-07-31 TW TW109125935A patent/TWI878330B/zh active
- 2020-07-31 PE PE2022000179A patent/PE20221021A1/es unknown
- 2020-07-31 AU AU2020324515A patent/AU2020324515A1/en active Pending
- 2020-07-31 EP EP20751505.7A patent/EP4007776A1/en active Pending
- 2020-07-31 WO PCT/EP2020/071660 patent/WO2021023658A1/en not_active Ceased
- 2020-07-31 CA CA3148937A patent/CA3148937A1/en active Pending
- 2020-07-31 KR KR1020227006480A patent/KR20220041161A/ko active Pending
- 2020-11-27 AR ARP200103306A patent/AR120585A1/es unknown
-
2022
- 2022-01-31 CL CL2022000252A patent/CL2022000252A1/es unknown
- 2022-01-31 IL IL290268A patent/IL290268A/en unknown
- 2022-02-01 MX MX2022011410A patent/MX2022011410A/es unknown
- 2022-02-01 MX MX2022011411A patent/MX2022011411A/es unknown
- 2022-02-25 CO CONC2022/0002044A patent/CO2022002044A2/es unknown
-
2023
- 2023-02-27 CL CL2023000562A patent/CL2023000562A1/es unknown
- 2023-10-09 US US18/483,174 patent/US20240052054A1/en not_active Abandoned
- 2023-12-13 US US18/538,242 patent/US12269881B2/en active Active
-
2024
- 2024-04-17 JP JP2024066707A patent/JP2024105296A/ja active Pending
-
2025
- 2025-02-11 US US19/050,553 patent/US20250215084A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105296A5 (enExample) | ||
| JP7724332B2 (ja) | クローディン１８．２結合部分およびその利用 | |
| JP6959970B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 | |
| CN105377886B (zh) | 识别mage-a1的高亲和力结合分子 | |
| JP2020512019A5 (enExample) | ||
| KR20220064986A (ko) | 항-pd-l1 단일-도메인 항체 및 그의 유도체 및 용도 | |
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| JP2020500523A5 (enExample) | ||
| CN119161491A (zh) | 双特异性重组蛋白及其应用 | |
| JP2018521008A (ja) | 腫瘍形成を処置するための治療用組成物および治療方法 | |
| BR112020024246A2 (pt) | pelo menos um polinucleotídeo recombinante, célula recombinante, receptor de antígeno quimérico, polinucleotídeo que codifica o receptor de antígeno quimérico, vetor, vírus, composição farmacêutica, e, método para tratar câncer | |
| JP2018518540A (ja) | 新規ｐｄ−１免疫調節剤 | |
| JP2010531140A5 (enExample) | ||
| CN114616337A (zh) | 嵌合CD3融合蛋白与基于anti-CD3的双特异性T细胞激活元件的联合表达 | |
| JP7193628B2 (ja) | 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用 | |
| US20250179173A1 (en) | Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor | |
| US20220332818A1 (en) | Bispecific antibody targeting pd-1 and tim-3 | |
| JP2023504149A (ja) | Ｃｄ３００ｃ抗原またはその受容体に特異的に結合するキメラ抗原受容体 | |
| IL297104A (en) | Antibodies to NKP46 and their constructs for the treatment of cancer and infections | |
| CN117603360A (zh) | 用于治疗癌症的多特异性抗体 | |
| CN114450028A (zh) | Lag-3拮抗剂治疗的定量空间剖析 | |
| CA3168743A1 (en) | Methods of treating cancer by administering a pd-1 inhibitor | |
| US20230277666A1 (en) | Chimeric antigen receptor comprising co-stimulatory receptor and application thereof | |
| CN116355099A (zh) | 重组抗人ox40和pd-l1双特异抗体及应用 | |
| WO2009147695A1 (ja) | 抗がん剤 |